Vol 19, No 1-2 (2017)
Original articles
Published online: 2018-07-02
Assessment of cotinine levels and selected inflammatory markers in patients after carotid endarterectomy
Chirurgia Polska 2017;19(1-2):1-6.
Abstract
Cardiovascular disease (CVD) is the leading mortality cause in western society. The main role in CVD development is played by atherosclerosis. Atherosclerosis is a long and complex process, in which are involved both lipid and immune system components, as well as environmental factors such as tobacco smoking. The aim of the study was to evaluate the influence of tobacco smoke exposure on parameters (lipoproteins, TGF-β1, MPO) associated with pathogenesis of atherosclerosis in patients undergoing carotid endarterectomy as a result of carotid artery stenosis. The study included 92 patients at the age of 47-82. Tobacco exposure was assessed according to cotinine blood level. No differences in the level of stenosis and concentration in serum of LDL, HDL, triglicerydes, Lp(a) and total cholesterol were observed between the smokers and non-smokers. TGF-β1 concentration was higher in non-smoking patients. Among smokers, cotinine level was correlated with MPO concentration
(p < 0,05). To conclude, tobacco smoking stimulates the inflammatory process and smooth muscle proliferation in the wall of carotid artery leading to atherogenesis.
Keywords: EndarterectomyTGF-β1nicotine abuse
References
- Fan J, Watanabe T. Inflammatory reactions in the pathogenesis of atherosclerosis. J Atheroscler Thromb. 2003; 10(2): 63–71.
- Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005; 352(16): 1685–1695.
- Libby P. Current Concepts of the Pathogenesis of the Acute Coronary Syndromes. Circulation. 2001; 104(3): 365–372.
- Borén J, Olin K, Lee I, et al. Identification of the principal proteoglycan-binding site in LDL. A single-point mutation in apo-B100 severely affects proteoglycan interaction without affecting LDL receptor binding. J Clin Invest. 1998; 101(12): 2658–2664.
- Libby P, Ridker PM, Maseri A, et al. Inflammation and Atherosclerosis. Circulation. 2002; 105(9): 1135–1143.
- Pentikäinen MO, Oörni K, Ala-Korpela M, et al. Modified LDL - trigger of atherosclerosis and inflammation in the arterial intima. J Intern Med. 2000; 247(3): 359–370.
- Berneis KK, Krauss RM. Metabolic origins and clinical significance of LDL heterogeneity. J Lipid Res. 2002; 43(9): 1363–1379.
- Li H, Horke S, Förstermann U. Vascular oxidative stress, nitric oxide and atherosclerosis. Atherosclerosis. 2014; 237(1): 208–219.
- Ishikawa Y, Kimura-Matsumoto M, Murakami M, et al. Distribution of smooth muscle cells and macrophages expressing scavenger receptor BI/II in atherosclerosis. J Atheroscler Thromb. 2009; 16(6): 829–839.
- Lewis GF, Rader DJ. New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ Res. 2005; 96(12): 1221–1232.
- Hansson GK, et al. Immune and inflammatory mechanisms in the pathogenesis of atherosclerosis. Arterioscler Thromb Vasc Biol. 2001; 21(12): 1876–1890.
- Shishehbor MH, Bhatt DL. Inflammation and atherosclerosis. Curr Atheroscler Rep. 2004; 6(2): 131–139.
- Ruiz E, Redondo S, Gordillo-Moscoso A, et al. Pioglitazone induces apoptosis in human vascular smooth muscle cells from diabetic patients involving the transforming growth factor-beta/activin receptor-like kinase-4/5/7/Smad2 signaling pathway. J Pharmacol Exp Ther. 2007; 321(2): 431–438.
- Jaffe M, Sesti C, Washington IM, et al. Transforming growth factor-β signaling in myogenic cells regulates vascular morphogenesis, differentiation, and matrix synthesis. Arterioscler Thromb Vasc Biol. 2012; 32(1): e1–11.
- Feinberg MW, Watanabe M, Lebedeva MA, et al. Transforming growth factor-beta1 inhibition of vascular smooth muscle cell activation is mediated via Smad3. J Biol Chem. 2004; 279(16): 16388–16393.
- Walshe TE, Dole VS, Maharaj ASR, et al. Inhibition of VEGF or TGF-{beta} signaling activates endothelium and increases leukocyte rolling. Arterioscler Thromb Vasc Biol. 2009; 29(8): 1185–1192.
- Grainger DJ, Mosedale DE, Metcalfe JC, et al. Active and acid-activatable TGF-beta in human sera, platelets and plasma. Clin Chim Acta. 1995; 235(1): 11–31.
- Meyer A, Wang W, Qu J, et al. Platelet TGF-β1 contributions to plasma TGF-β1, cardiac fibrosis, and systolic dysfunction in a mouse model of pressure overload. Blood. 2012; 119(4): 1064–1074.
- Lutgens E, Gijbels M, Smook M, et al. Transforming growth factor-beta mediates balance between inflammation and fibrosis during plaque progression. Arterioscler Thromb Vasc Biol. 2002; 22(6): 975–982.
- Dai J, Michineau S, Franck G, et al. Long term stabilization of expanding aortic aneurysms by a short course of cyclosporine A through transforming growth factor-beta induction. PLoS One. 2011; 6(12): e28903.
- Ji Qw, Guo M, Zheng Js, et al. Downregulation of T helper cell type 3 in patients with acute coronary syndrome. Arch Med Res. 2009; 40(4): 285–293.
- Redondo S, Navarro-Dorado J, Ramajo M, et al. The complex regulation of TGF-β in cardiovascular disease. Vasc Health Risk Manag. 2012; 8: 533–539.
- Kieć-Wilk B, Stolarz-Skrzypek K, Sliwa A, et al. Peripheral blood concentrations of TGFβ1, IGF-1 and bFGF and remodelling of the left ventricle and blood vessels in hypertensive patients. Kardiol Pol. 2010; 68(9): 996–1002.
- Pallero MA, Talbert Roden M, Chen YF, et al. Stainless steel ions stimulate increased thrombospondin-1-dependent TGF-beta activation by vascular smooth muscle cells: implications for in-stent restenosis. J Vasc Res. 2010; 47(4): 309–322.
- McCaffrey TA, Du B, Fu C, et al. The expression of TGF-beta receptors in human atherosclerosis: evidence for acquired resistance to apoptosis due to receptor imbalance. J Mol Cell Cardiol. 1999; 31(9): 1627–1642.
- Sakamoto Yi, Miyazaki A, Tamagawa H, et al. Specific interaction of oxidized low-density lipoprotein with thrombospondin-1 inhibits transforming growth factor-beta from its activation. Atherosclerosis. 2005; 183(1): 85–93.
- Klebanoff SJ. Oxygen metabolism and the toxic properties of phagocytes. Ann Intern Med. 1980; 93(3): 480–489.
- Zhang R, Brennan ML, Shen Z, et al. Myeloperoxidase functions as a major enzymatic catalyst for initiation of lipid peroxidation at sites of inflammation. J Biol Chem. 2002; 277(48): 46116–46122.
- Nicholls SJ, Hazen SL. Myeloperoxidase, modified lipoproteins, and atherogenesis. J Lipid Res. 2009; 50 Suppl: S346–S351.
- Hazen SL, Heinecke JW. 3-Chlorotyrosine, a specific marker of myeloperoxidase-catalyzed oxidation, is markedly elevated in low density lipoprotein isolated from human atherosclerotic intima. J Clin Invest. 1997; 99(9): 2075–2081.
- Niccoli G, Dato I, Crea F. Myeloperoxidase may help to differentiate coronary plaque erosion from plaque rupture in patients with acute coronary syndromes. Trends Cardiovasc Med. 2010; 20(8): 276–281.
- Ali M, Li Y, O'Neal WT, et al. Tobacco Exposure as Determined by Serum Cotinine and Subclinical Myocardial Injury in Individuals Free from Cardiovascular Disease. Am J Cardiol. 2017; 120(7): 1114–1117.
- Al Rifai M, DeFilippis AP, McEvoy JW, et al. The relationship between smoking intensity and subclinical cardiovascular injury: The Multi-Ethnic Study of Atherosclerosis (MESA). Atherosclerosis. 2017; 258: 119–130.
- Garbin U, Fratta Pasini A, Stranieri C, et al. Cigarette smoking blocks the protective expression of Nrf2/ARE pathway in peripheral mononuclear cells of young heavy smokers favouring inflammation. PLoS One. 2009; 4(12): e8225.
- Yamaguchi Yu, Matsuno S, Kagota S, et al. Peroxynitrite-mediated oxidative modification of low-density lipoprotein by aqueous extracts of cigarette smoke and the preventive effect of fluvastatin. Atherosclerosis. 2004; 172(2): 259–265.
- Kangavari S, Matetzky S, Shah PK, et al. Smoking increases inflammation and metalloproteinase expression in human carotid atherosclerotic plaques. J Cardiovasc Pharmacol Ther. 2004; 9(4): 291–298.
- Cavusoglu Y, Timuralp B, Us T, et al. Cigarette smoking increases plasma concentrations of vascular cell adhesion molecule-1 in patients with coronary artery disease. Angiology. 2004; 55(4): 397–402.
- Siasos G, Tsigkou V, Kokkou E, et al. Smoking and atherosclerosis: mechanisms of disease and new therapeutic approaches. Curr Med Chem. 2014; 21(34): 3936–3948.
- Messner B, Bernhard D. Smoking and cardiovascular disease: mechanisms of endothelial dysfunction and early atherogenesis. Arterioscler Thromb Vasc Biol. 2014; 34(3): 509–515.
- Sirpal S. Myeloperoxidase-mediated lipoprotein carbamylation as a mechanistic pathway for atherosclerotic vascular disease. Clin Sci (Lond). 2009; 116(9): 681–695.
- Hansson GK, Libby P. The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol. 2006; 6(7): 508–519.
- Cucina A, Sapienza P, Corvino V, et al. Nicotine-induced smooth muscle cell proliferation is mediated through bFGF and TGF-beta 1. Surgery. 2000; 127(3): 316–322.
- Liu CC, Yeh HI. Nicotine: A Double-Edged Sword in Atherosclerotic Disease. Acta Cardiol Sin. 2014; 30(2): 108–113.
